RESEARCH PAPER
Prostate cancer in patients from rural and suburban areas – PSA value, Gleason score and presence of metastases in bone scan
1
Hygiene and Diet Department, Jagiellonian University Medical College, Cracow, Poland
2
Nuclear Medicine Department, John Paul II Hospital, Cracow, Poland
3
Cardiovascular Diseases Department, Jagiellonian University Medical College, Cracow, Poland
4
Higher School of Public Health, Zielona Góra, Poland
5
Department for Health Problems of Ageing, Institute of Rural Health, Lublin, Poland
Corresponding author
Ann Agric Environ Med. 2014;21(4):888-892
KEYWORDS
ABSTRACT
Introduction:
Prostate cancer is the second most common neoplasm among men both worldwide and in Poland. In prostate cancer, bone metastasis is related to a poorer prognosis. A diagnosis of metastatic bone disease is important in prostate cancer patients prior to therapy. Prostate specific antigen (PSA) serum value is used both as a screening tool and for staging of prostate cancer.
Aim:
To evaluate whether there is a link between symptoms presented by patients, pain in particular, and the presence, number and location of bone metastases as assessed by bone scan scintigraphy in concordance with PSA values and Gleason scores.
Material and Methods:
A group of 186 patients (aged: 68.38±6.16) diagnosed with prostate cancer, from rural and suburban areas of Małopolska province, that was directed for bone scan scintigraphy to the Nuclear Medicine Dept, John Paul II Hospital in Kraków. Analysis of all laboratory findings (including PSA value) and a biopsy were performed. Then, bone scan scintigraphy was done with the use of methylene disphosphonate (MDP) labeled with Tc-99m.
Results:
In patients with a Gleason value ≤7 and a PSA value ≤20 ng/ml, the cutoff value for a negative bone scan with a confidence interval of 0.95 was established at a PSA value below 10 ng/ml (p<0.01). Correlations were established between PSA value and presence of metastases in bone scan (r=0.45, p=0.05), the number of metastases (r=0.66, p<0.01), and their presence in particular body regions.
Conclusions:
The correlation between PSA value and both presence and number of metastases confirms the usefulness of bone scan scintigraphy in prostate cancer staging. The cutoff value for negative bone scan with a 95% confidence interval was established at PSA = 10 ng/ml.
Prostate cancer is the second most common neoplasm among men both worldwide and in Poland. In prostate cancer, bone metastasis is related to a poorer prognosis. A diagnosis of metastatic bone disease is important in prostate cancer patients prior to therapy. Prostate specific antigen (PSA) serum value is used both as a screening tool and for staging of prostate cancer.
Aim:
To evaluate whether there is a link between symptoms presented by patients, pain in particular, and the presence, number and location of bone metastases as assessed by bone scan scintigraphy in concordance with PSA values and Gleason scores.
Material and Methods:
A group of 186 patients (aged: 68.38±6.16) diagnosed with prostate cancer, from rural and suburban areas of Małopolska province, that was directed for bone scan scintigraphy to the Nuclear Medicine Dept, John Paul II Hospital in Kraków. Analysis of all laboratory findings (including PSA value) and a biopsy were performed. Then, bone scan scintigraphy was done with the use of methylene disphosphonate (MDP) labeled with Tc-99m.
Results:
In patients with a Gleason value ≤7 and a PSA value ≤20 ng/ml, the cutoff value for a negative bone scan with a confidence interval of 0.95 was established at a PSA value below 10 ng/ml (p<0.01). Correlations were established between PSA value and presence of metastases in bone scan (r=0.45, p=0.05), the number of metastases (r=0.66, p<0.01), and their presence in particular body regions.
Conclusions:
The correlation between PSA value and both presence and number of metastases confirms the usefulness of bone scan scintigraphy in prostate cancer staging. The cutoff value for negative bone scan with a 95% confidence interval was established at PSA = 10 ng/ml.
REFERENCES (22)
1.
Ferlay J. Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 Lyon. International Agency for Research on Cancer, France 2010 http://globocan.iarc.fr/Defaul... (access: 2013.05.27).
2.
Schröder FH, Wildhagen MF. Rotterdam Study Group of the ‘European Randomised Study of Screening for Prostate Cancer’ (ERSPC). Screening for prostate cancer: evidence and perspectives. BJU Int. 2001; 88: 811–817.
3.
Parnes HL, House MG, Tangrea JA. Prostate cancer prevention: strategies for agent development. Curr Opin Oncol. 2013; 25(3): 242–251.
4.
Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening. diagnosis. and treatment of clinically localised disease. Eur Urol. 2011; 59(1): 61–71.
5.
Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. (2008) EAU guidelines on prostate cancer. Eur Urol. 2008. 53:68–80.
6.
Kosuda S, Yoshimura I, Aizawa T, Koizumi K, Akakura K, Kuyama J, et al. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan. Cancer 2002; 94: 964–972.
7.
Liu D, Wang W, Qiao LD, Zheng YP, Liu YX, Zhang GY, et al. The indication of bone scan for patients with newly diagnosed prostate cancer. Zhonghua Wai Ke Za Zhi. 2012; 50: 443–445.
8.
De Nunzio C, Leonardo C, Franco G, Esperto F, Brassetti A, Simonelli G, et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of a novel risk stratification tool. World J Urol. 2013; 31(2): 365–369.
9.
O’Sullivan JM, Norman AR, Cook GJ, Fisher C, Dearnaley DP. Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital. BJU Int. 2003; 92: 685–919.
10.
Misailidou V, Malliou P, Beneka A, Karagiannidis A, Godolias G. Assessment of patients with neck pain: a review of definitions. selection criteria. and measurement tools. J Chiropr Med. 2010; 9: 49–59.
11.
Ataus S, Citçi A, Alici B, Onder AU, Sönmezoğlu K, Erözenci A, et al. The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer. Int Urol Nephrol. 1999; 31: 481–489.
12.
Rydh A, Tomic R, Tavelin B, Hietala SO, Damber JE. Predictive value of prostate-specific antigen, tumour stage and tumour grade for the outcome of bone scintigraphy in patients with newly diagnosed prostate cancer. Scand J Urol Nephrol. 1999; 33: 89–93.
13.
Bantis A, Grammaticos P. Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased? Hell J Nucl Med. 2012; 15(3): 241–246.
14.
Briganti A, Passoni N, Ferrari M, Capitanio U, Suardi N, Gallina A, et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol. 2010; 57: 551–558.
15.
Tanaka N, Fujimoto K, Shinkai T, Nakai Y, Kuwada M, Anai S, et al: Bone scan can be spared in asymptomatic prostate cancer patients with PSA of ≤20 ng/ml and Gleason score of ≤6 at the initial stage of diagnosis. Jpn J Clin Oncol. 2011; 41: 1209–1213.
16.
Maślach D, Krzyżak M, Szpak A, Owoc A, Gębska-Kuczerowska A, Bielska-Lasota M. Differences in results of breast cancer curative treatment between urban/rural female population in Podlaskie Voivodship of Poland before introduction of the National Cancer Control Programme. Ann Agric Environ Med. 2013; 20(1): 68–71.
17.
Sawicki M, Szczyrek M, Krawczyk P, Rybojad P, Jabłonka A, Milanowski J. Reasons for delay in diagnosis and treatment of lung cancer among patients in Lublin Voivodeship who were consulted in Thoracic Surgery Department. Ann Agric Environ Med. 2013; 20(1): 72–76.
18.
Lee N, Fawaaz R, Olsson CA, Benson MC, Petrylak DP, Schiff PB. et al. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys. 2000; 48: 1443–1446.
19.
Pal RP, Thiruudaian T, Khan MA. When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer? Asian J Androl. 2008; 10: 890–895.
20.
Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007; 243: 28–53.
21.
Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, et al: Prognostic value of serum markers for prostate cancer. Scand J Urol Nephrol Suppl. 2005; 216: 64–81.
22.
Carmona Echeverria LM, Drudge-Coates L, Wilkins CJ, Muir GH. Bone scan is of doubtful value as a first staging test in the primary presentation of prostate cancer. ISRN Oncol. 2012; 2012: 585017.
Share
RELATED ARTICLE
| eISSN: | 1898-2263 |
| ISSN: | 1232-1966 |
Improvement of visual identification of the journal - task financed under the agreement No. 618/P-DUN/2019 by the Minister of Science and Higher Education allocated to the activities of disseminating science.
Generation of the DOI (Digital Object Identifier) - task financed under the agreement No. 618/P-DUN/2019 by the Minister of Science and Higher
© 2006-2024 Journal hosting platform by Bentus
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
